Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Newer neuromuscular blocking agents

D R Bevan1

  • 1UBC Department of Anaesthesia, Vancouver General Hospital, B.C., Canada.

Pharmacology & Toxicology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Four new neuromuscular blocking drugs offer safe options for anesthesia, with varying durations of action. While rocuronium provides rapid onset and mivacurium offers quick recovery, succinylcholine remains unique for urgent airway control.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose-related effects of succinylcholine on the adductor pollicis and masséter muscles in children.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2016
Same author

Jaw muscle tension after succinychloline in children undergoing strabismus surgery.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2016
Same author

Dr R. A. Gordon 1911-1998.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2016
Same author

Neuromuscular blockade. Inadvertent extubation of the partially paralyzed patient.

Anesthesiology clinics of North America·2002
Same author

Anaesthesia research is important.

European journal of anaesthesiology. Supplement·2002
Same author

Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient.

Anesthesiology·2001
Same journal

Spontaneous reversal of p-glycoprotein expression in multidrug resistant cell lines.

Pharmacology & toxicology·2003
Same journal

Melatonin protects against mercury(II)-induced oxidative tissue damage in rats.

Pharmacology & toxicology·2003
Same journal

Inhibition by uric acid of free radicals that damage biological molecules.

Pharmacology & toxicology·2003
Same journal

In vitro induction of differentiation by ginsenoside Rh2 in SMMC-7721 hepatocarcinoma cell line.

Pharmacology & toxicology·2003
Same journal

Mepivacaine alters vascular responsiveness to vasoconstrictors in aortic rings from normal and aortic-banded rats.

Pharmacology & toxicology·2003
Same journal

6-Ethyl-N,N'-bis(3-hydroxyphenyl)[1,3,5]triazine-2,4-diamine (RS-0466) enhances the protective effect of brain-derived neurotrophic factor on amyloid beta-induced cytotoxicity in cortical neurones.

Pharmacology & toxicology·2003
See all related articles

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • Four new neuromuscular blocking drugs (doxacurium, mivacurium, pipecuronium, rocuronium) are entering clinical practice.
  • These drugs represent two distinct chemical classes: benzylisoquinolines and aminosteroids.
  • Existing neuromuscular blocking agents have limitations that necessitate new options.

Purpose of the Study:

  • To review the pharmacology of four new neuromuscular blocking drugs.
  • To evaluate their suitability for clinical anesthetic practice.
  • To assess if these agents meet the needs of clinicians.

Main Methods:

  • Pharmacological review of doxacurium, mivacurium, pipecuronium, and rocuronium.
  • Comparison of their properties with existing neuromuscular blocking agents.

Related Experiment Videos

  • Analysis of clinical applications and clinician needs.

    • Main Results:

    • Doxacurium and pipecuronium are long-acting; rocuronium has an intermediate duration with rapid onset (max effect in 2 min).
    • Mivacurium is unique, metabolized by plasma cholinesterase, allowing rapid recovery.
    • All new drugs are safe with no significant cardiovascular side effects.

    Conclusions:

    • A range of safe, non-depolarizing muscle relaxants with diverse action durations are now available.
    • Succinylcholine's unique rapid onset and recovery for urgent airway management remain essential.
    • The search for a non-depolarizing alternative to succinylcholine will continue.